The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Current therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this setting. Vimentin plays a role in carcinogenesis through the activation of the...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Bronte, Giuseppe, Puccetti, Maurizio, Petracci, Elisabetta, Landi, Lorenza, Cravero, Paola, Scodes, Simona, Ulivi, Paola, Ravaioli, Sara, Tumedei, Maria Maddalena, Burgio, Marco Angelo, Cappuzzo, Federico, Delmonte, Angelo, Crinò, Lucio, Bravaccini, Sara
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2021
נושאים:
Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130554/
https://ncbi.nlm.nih.gov/pubmed/34017688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.669839
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים